Leukocyte adhesion deficiency type-I (LAD-I) is an autosomal recessive immunodeficiency caused by mutations in the β2 integrin, CD18, which impair CD11/CD18 heterodimer surface expression and/or function. Absence of functional CD11/CD18 integrins on leukocytes, particularly neutrophils, leads to their incapacity to adhere to the endothelium and migrate to sites of infection. We studied three LAD-1 patients with markedly diminished neutrophil CD18 expression, each of whom had a small population of lymphocytes with normal CD18 expression (CD18+). These CD18+ lymphocytes were predominantly cytotoxic T cells, with a memory/effector phenotype. Microsatellite analyses proved patient origin of these cells. Sequencing of T cell subsets showed that in each patient one CD18 allele had undergone further mutation. Interestingly, all three patients were young adults with inflammatory bowel disease. Somatic reversions of inherited mutations in primary T cell immunodeficiencies are typically associated with milder clinical phenotypes. We hypothesize that these somatic revertant CD18+ cytotoxic T lymphocytes (CTL) may have altered immune regulation. The discovery of 3 cases of reversion mutations in LAD-1 at one center suggests that this may be a relatively common event in this rare disease.
ABSTRACT:
Leukocyte adhesion deficiency type-I (LAD-I) is an autosomal recessive immunodeficiency caused by mutations in the β2 integrin, CD18, which impair CD11/CD18 heterodimer surface expression and/or function. Absence of functional CD11/CD18 integrins on leukocytes, particularly neutrophils, leads to their incapacity to adhere to the endothelium and migrate to sites of infection. We studied three LAD-1 patients with markedly diminished neutrophil CD18 expression, each of whom had a small population of lymphocytes with normal CD18 expression (CD18+). These CD18+ lymphocytes were predominantly cytotoxic T cells, with a memory/effector phenotype. Microsatellite analyses proved patient origin of these cells. Sequencing of T cell subsets showed that in each patient one CD18 allele had undergone further mutation. Interestingly, all three patients were young adults with inflammatory bowel disease. Somatic reversions of inherited mutations in primary T cell immunodeficiencies are typically associated with milder clinical phenotypes. We hypothesize that these somatic revertant CD18+ cytotoxic T lymphocytes (CTL) may have altered immune regulation. The discovery of 3 cases of reversion mutations in LAD-1 at one center suggests that this may be a relatively common event in this rare disease.
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INTRODUCTION:
Somatic mosaicism due to site-specific reversions of inherited mutations to wild type have received much attention in the last decade [1] [2] [3] [4] [5] [6] [7] . Some of these reversions have expanded in the host, leading to speculation about possible survival advantages conferred on the cell population carrying the reverted normal sequence. The events leading to somatic mosaicism as a result of reversion of inherited mutations to normal are in principal different from germ line mosaicism or somatic mosaicism due to de novo mutation 7 . Pathologic mutations that have reverted to wild type have been considered paradigms of endogenous somatic gene therapy 5, [8] [9] [10] . Unusual phenotypes have alerted investigators to this sort of mosaicism, such as a milder-than-expected disease course, progressive improvement of disease, or detection of phenotypically normal and abnormal cells. Several different mechanisms have been suggested to be responsible for these events: intragenic recombination, mitotic gene conversion, second site mutations, DNA slippage, and site-specific reversion to normal. The "back mutation" or "repair" process is most likely random and may reflect an increased mutation rate in certain disorders or mutational hotspots 7, 8, 11 . Somatic reversions have been described in epidermolysis bullosa, tyrosinaemia type I, Duchenne muscular dystrophy, Lesch-Nyhan disease, Charcot-Marie-Tooth disease type 1A, and Fanconi anemia [11] [12] [13] [14] . Among the primary immunodeficiencies, reversions in adenosine deaminase deficiency, X-linked severe combined immunodeficiency and Wiskott-Aldrich Syndrome, confer selective growth advantage on the corrected cells 1, 2, 4, 5, 9, 10 .
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From Leukocyte adhesion deficiency type-1 (LAD-1) is an autosomal recessive disease caused by mutations in the gene encoding CD18 [15] [16] [17] . It is characterized by absent or dramatically diminished expression of the CD11/CD18 integrins or the expression of non-functional forms of these integrins [17] [18] [19] [20] . Cellular manifestations of LAD-1 include defective polymorphonuclear chemotaxis, margination, adherence, phagocytosis of complement-coated particles and bacterial killing, as well as diminished natural killer (NK) cell function and cytotoxic T-lymphocyte (CTL) activity. Affected patients have elevated blood neutrophil counts, frequent life-threatening systemic, skin and soft tissue infections, and severe periodontitis and gingivitis
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. Inflammatory bowel disease has been reported in several LAD-1 patients 21, 22 . Even though the heterogeneity of clinical phenotype has been linked to the diversity of CD18 mutations, Shaw et al found biochemical correlation between genotype and phenotype in three LAD-1 patients with residual CD11/CD18 expression and function 23 . During routine evaluation of CD18 expression on leukocytes of 3 LAD-1 patients, we found small populations of CD18+ lymphocytes, in addition to the major CD18-populations. We subsequently identified these CD18+ populations as somatic revertants. In this report we describe these reversion mutations in LAD-1 lymphocytes and their effects on function.
MATHERIALS AND METHODS:
Patients were enrolled to protocol 93-I-0119 approved NIAID institutional review board. They have provided informed consent. Entire clinical investigation has been conducted according to Declaration of Helsinki principles. 21 . At 35, he was started on infliximab for LAD-1 associated colitis, to which he has responded very well.
Flow Cytometric analysis:
Peripheral blood specimens were collected into EDTA containing tubes. PBMCs were purified from whole blood using density gradient centrifugation.
Cells were stained using anti-CD3 and anti-CD18 antibodies. CD3+/CD18+ and CD3+/CD18-cells were sorted using a BD FacsVantage (Becton-Dickinson, Mountain View, CA). Purity analysis and cell counts were done after sorting.
Genomic DNA isolation from the sorted CD3+/CD18+ and CD3+/CD18-cells was done using Gentra Puregene cell kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.
Microsatellite analysis:
Genomic DNA isolated from the sorted CD3+/CD18+ and CD3+/CD18-cells was compared by analysis of microsatellite DNA sequences. Seven distinct microsatellite sequences were amplified by the polymerase chain reaction (PCR) with a multiplexed PCR kit (Ampfister Profiler, Perkin-Elmer Applied Biosystems, Foster City, CA). The PCR product was run on an automated sequencer (model 310, Perkin-Elmer Applied Biosystems, Foster City, CA) and analyzed with GeneScan software (ABI Prism, version 3.1, Foster City, CA). We assessed the data for unique microsatellite polymorphisms that would be indicative of hemotopietic chimerism 30 .
PCR amplification and cloning of mutant DNA fragments:
The following primers (Invitrogen, Carlsbad, CA) were used to amplify the given mutation sites: For 
Sequence analysis and screening of clones:
Direct sequencing of the purified DNAs was carried out to screen the clones using a Model 377 Applied Biosystems sequencer and Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA).
Sequence was analyzed with Sequencher 3.1.1. software (Gene Codes, Ann
Arbor, MI).
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Transfection and adhesion assays:
Monoclonal antibodies used for expression analysis of transfected cells have been described previously 31, 32 . Mutant cDNA fragments were created using site directed mutagenesis, cloned into pcDNA3 vector (Invitrogen BV, Groningen, Netherlands) and transfected into COS-7 cells as described 23 . The monoclonal antibody 1B4, which is specific for CD11/CD18 heterodimers, was used to measure the expression of the heterodimers on COS-7 cells transfected with CD11 alone or co-transfected with either wild-type, mutant or revertant CD18.
Adhesion has been described previously 23 . Briefly, microtitre wells were coated with ICAM-Fc or iC3b as described. COS-7 transfectants were resuspended in RPMI-1640 with 10 mM HEPES, pH 7. 
CD18+ T Cell Superantigen Response:
PBMCs from healthy controls and the 3 patients were cultured either in complete media alone, or in combination with SEB (Sigma-Aldrich, St. Louis, MO) and IL-2 (Chiron Corporation, Emeryville, CA) for 6 days. Expansion of the CD18+ lymphocyte population was analyzed by flow cytometry using specific surface markers.
RESULTS:

Mosaicism of CD18 Expression in T Cells in patients with LAD-1:
Flow cytometry were used to evaluate CD18 expression of peripheral blood polymorphonuclear cells (PMNs) and lymphocytes. All 3 LAD-1 patients had single populations of PMNs with very dim CD18 staining as compared to control (Figure 1a) . Intensity of staining was calculated using relative fluorescence intensity (RFI), which is geometric mean channel (GMC) for CD18 divided by . Sequencing of the amplified overlapping segments revealed that patient 1 had a novel homozygous missense mutation A→C at nt 392, resulting in Y131S (Figure 2a) . We also verified this mutation by sequencing genomic DNA extracted from stored frozen PMNs of the patient, as well as from extracted genomic DNA from a paraffin embedded skin biopsy. The same homozygous A392C leading to Y131S change was found in PCR amplified genomic DNA from skin. Therefore, there was no evidence of mosaicism for this missense mutation in skin tissue and PMNs. To verify that the reversion mutation occurred in the patient and was not an inherited allele from a parent, genomic DNA was obtained from buccal epithelial cells of both parents. Both parents were heterozygous for A→C at nt 392 and the wild type allele only. The mutations in patients 2 and 3 have been previously published 17, 20, [26] [27] [28] 33 . 
with homozygous genomic deletions of ~1500 bases in ITGB2 spanning exons 12 and 13 (not previously reported). Subject C was born in 1981 and died of fungal sepsis at age 12 16, 34 . He was homozygous for C→A mutation at nt 1602 leading to 534X. Subject D was born in 1995 and had a compound hereozygous phenotype of G→A missense mutation at nt 850 resulting in G284S and delT at nt 2142 in exon 14 resulting in a premature truncation (not previously reported).
Reversion Mutations in CD18+ Lymphocyte Populations:
Genomic DNA was obtained from sorted CD3+/CD18+ and CD3+/ CD18-lymphocytes from each of our three patients. Mutation site-specific amplification, sub-cloning and sequencing was performed. All of the CD18-clones (10/10) from patient 1 were homozygous for A→C at nt 392 leading to Y131S (Figure 2b ). In contrast, 4/10 CD18+ clones showed A→T at nt 392, which encodes Y131F. The remaining 6/10 CD18+ clones had the original missense mutation A→C at nt 392. This indicated a heterozygous forward mutation of Y131 from 131S to 131F (TCT, serine to TTT, phenylalanine). Because of the homozygosity of the inherited original mutation Y131S, neither gene conversion nor crossing over could be the mechanisms. Two of ten PCR clones had a second site mutation C→G at nt 852, in addition to the original mutation G→A at nt 850, also leading to arginine at 284 (AGG) (Figure 2b ). Therefore, a subset of CD18+ T cells were phenotypically identical, all with an arginine in position 284, but using two different codons. Half of the CD18+ clones carried the original mutation, while the other half had changes leading to the same amino acid (arginine), which is in agreement with the hypothesis that the forward mutations only took place on one of the two alleles. Cells were analyzed for their CD18 expression by flow cytometry. Expansion of CD18+ cells, determined by fold increase in CD18+ expression following stimulation with SEB and IL-2 as opposed to media alone was 7.6, 5.6 and 3.1 fold for the 3 LAD-1 patients, respectively. Since CD18 is constitutively expressed by all lymphocytes in normal controls and >95% of control cells were already CD18+ in media alone, no significant change was observed for control cells. Based on this favorable expansion of CD18+ revertant cells from 3 patients, we concluded that the reverted CD18 molecules supported proliferation to superantigen (SEB) and IL-2 better than the mutated CD18 (data not shown).
Functional evaluation of the Reversion Mutations:
The two missense mutations (Y131S and G284S) and their corresponding revertants (Y131F and G284R) were created by site-directed mutagenesis and each separately introduced into CD18 cDNA in the expression vector pcDNA3, as previously described 23 . Each construct was transfected into COS-7 cells together with the cDNA for either CD11a, CD11b, or CD11c, also expressed in pcDNA3. Binding of the revertant Y131F to ICAM-1 was activated to wild type levels with Mg 2+ /EGTA or KIM185 (Figure 5a ). The revertant G284R did not bind to ICAM-1.
Adhesion of LFA-1 to ICAM-2 and ICAM-3 was studied (Figure 5b, 5c ).
LFA-1 with the Y131F revertant binds similarly to wild-type LFA-1, but the revertant G284R did not bind to ICAM-2 and ICAM-3.
MAC-1 (CD11b/CD18) and p150,95 (CD11c/CD18) adhesion to iC3b upon activation with MnCl 2 or KIM185 showed no binding when CD18 contained the Y131S or G284S mutations (Figure 6a, 6b) . However, both revertants Y131F and G284R were activated to bind iC3b to levels similar to the wild-type. Therefore, the initial mutant CD18 proteins of patients 1 and 2 are dysfunctional in terms of adhesion to specific ligands. The revertant form of CD18 protein from patient 1 (Y131F) can support co-expression of CD18 and all 3 alpha chains. The revertant form of CD18 from patient 2 (G284R), however, can only support the expression and functions for CD11b/CD18 and CD11c/CD18, but not CD11a/CD18.
DISCUSSION:
We have identified three adult LAD-1 patients with somatic mosaicism who survived into adulthood without allogeneic bone marrow transplants. In all three patients the reversion mutations were heterozygous. None of the other known mechanisms of reversion in the cases described were evident 8, 11 . Allelic change was observed only in the genomic DNA from a small subset of circulating CD8+ T cells, but not in neutrophils, monocytes, CD4+ T cells, or B cells.
Microsatellite analyses proved that the lymphocytes carrying both the mutant and revertant CD18 alleles were endogenous in each patient, ruling out the possibility of persistently engrafted maternal or allogeneic T cells. In two patients with different homozygous missense mutations, reversion was only detected on one of the two alleles. In these patients' CD18+ T cells, reversion was not to the wildtype but to a third amino acid. A single case of somatic reversion of a LAD-1 mutation to WT was recently reported 35 . In that compound heterozygous patient, reversion to WT was detected on one allele in a subset of T cells, presumably inducing normal binding and function, similar to previous reports of somatic reversion to WT, as seen in our patient 3. In contrast to that report and most reports in patients with immunodeficiency 1,2,4,5,9,10 , our patients 1 and 2 had novel reversions that partially or fully restored the function but were not WT.
Therefore, our patients illustrate clearly that it is the reversion to relatively normal function that is important in the expansion of these cells, and not the reversion to WT sequence.
Rare cases of somatic mosaicism resulting from reversion of inherited mutations have been reported that lead to attenuation of blood-cell disorders [1] [2] [3] [4] [5] [6] 8 .
The Since the reverted amino acid sequences in our patients were not among the reported polymorphisms of CD18, functional analyses were critical. CD18
with the 131F revertant was functional, as determined by heterodimer formation We were unable to identify reversions in progenitor cells, neutrophils or monocytes indicating that these events did not take place at a pluripotent stem cell level, but occurred in lineage-committed precursors. Even if the reversion occurred in a multipotent hematopoietic progenitor, it did not appear to confer proliferative advantage outside the T-cell lineage. Alternatively, these patients may have been born T-cell mosaics for CD18 expression, or they may have reverted early in life. Although it is theoretically possible that CD18+ myeloid cells could be formed and transit to the tissue without detection in the peripheral blood, we found no evidence of CD18+ staining in bowel biopsies nor did we find any CD18+ stem cells in the circulation (data not shown). We are unable to determine the earliest time point these cells were detectable in peripheral blood since we do not have PBMCs dating as early as birth or infancy. However, the absence of these reverted alleles in their parents proves that these reversion mutations are endogenous to our patients.
The interaction and cross activation of TCR and CD18 is important, as is the role of CD18 in CD8+ T cell homing, recirculation and survival 39, 40 . These reversion mutations illustrate the need to look carefully at unusual patients and to Fig. 5b) and ICAM-3 (Fig. 5c) . Adhesion was done in the absence of activating agents, in the presence of 1.5 mM EGTA and 5 mM MgCl 2 (Mg/EGTA), or with the activating monoclonal antibody KIM185 (2.5 µg/ml) or with both Mg/EGTA and KIM185 (for ICAM-2 and ICAM-3 only). CD18 independent adhesion (background) was determined by inhibition with monoclonal antibody 1B4 (10 µg/ml) and has been subtracted. 
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